Characteristics | Patients |
---|---|
N (%) | |
Gender | |
Male | 18 (53%) |
Female | 16 (47%) |
Age (median, range) | 60 (29–85) |
ECOG PS | |
0 | 2 (6%) |
1 | 17 (50%) |
2 | 12 (35%) |
3 | 3 (9%) |
Tumour site | |
Stomach | 11 (32.4%) |
Small Intestine | 10 (29.4%) |
Mesentery | 7 (20.6%) |
Other | 6 (17.6%) |
(peritoneum3, colon 1, rectum 1, oesophagus 1) | |
Metastatic sites | |
Liver | 28 (82%) |
Peritoneum | 25 (73.5%) |
Lung | 4 (12%) |
Other | 10 (29.5%) |
Transfusion before EPO treatment | |
Yes | 10 (29%)/ |
No | 24 (71%) |
Starting Dose of Imatinib/day | |
400 mg | 25(67.6%) |
800 mg | 9(11.7%) |